High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

MLA

Yuen, Kobe C., et al. “High Systemic and Tumor-Associated IL-8 Correlates with Reduced Clinical Benefit of PD-L1 Blockade.” Nature Medicine, vol. 26, no. 5, May 2020, p. 693. EBSCOhost, https://doi.org/10.1038/s41591-020-0860-1.

APA

Yuen, K. C., Liu, L.-F., Gupta, V., Madireddi, S., Keerthivasan, S., Li, C., Rishipathak, D., Williams, P., Kadel, E. E., III, Koeppen, H., Chen, Y.-J., Modrusan, Z., Grogan, J. L., Banchereau, R., Leng, N., Thastrom, A. C., Shen, X., Hashimoto, K., Tayama, D., … Mariathasan, S. (2020). High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nature Medicine, 26(5), 693. https://doi.org/10.1038/s41591-020-0860-1

Chicago

Yuen, Kobe C., Li-Fen Liu, Vinita Gupta, Shravan Madireddi, Shilpa Keerthivasan, Congfen Li, Deepali Rishipathak, et al. 2020. “High Systemic and Tumor-Associated IL-8 Correlates with Reduced Clinical Benefit of PD-L1 Blockade.” Nature Medicine 26 (5): 693. doi:10.1038/s41591-020-0860-1.